573P Role of CA125 in Patients Included in the DESKTOP III/ENGOT-ov20 Trial

F. Lecuru,J. Sehouli,I.B. Vergote,A. Reuss,J-M. Classe,P. Hillemanns,S. Greggi,M.R. Mirza,P.E. Brachet,P. Follana,N. Raban,A. Hasenburg,R. Zang,K. Lindemann,J-W. Kim,A. Poveda,F. Raspagliesi,C.A. Haslund,A. du Bois,P. Harter

DOI: https://doi.org/10.1016/j.annonc.2022.07.701

IF: 51.769

2022-01-01

Annals of Oncology

Abstract:Complete resection significantly improves survival in ovarian cancer patients with a platinum sensitive recurrence who fulfil the AGO score. We assessed the association of levels of CA125 at relapse with surgical and oncological outcome. CA125 at the time of surgery was classified as normal (Group A: <35 U/ml) versus elevated (Group B: 35 U/ml - 350 U/ml) versus strongly elevated (Group C: > 350 U/ml). We assessed surgical outcome by CA125 and explored the prognostic value of CA125. Baseline CA125 was available in 91% (370/407) of randomized patients, 181 randomized to chemotherapy alone and 189 to additional surgery. Median CA125 values and classified cohorts did not differ significantly between patients in the chemotherapy arm vs patients in the surgical arm. The complete resection rate in the 176 patients undergoing surgery was 74% (group A versus B versus C: 83% (48/58) and 72% (74/103) and 53% (8/15) (p=0.053), respectively). There were no relevant differences regarding surgical procedures, but there was a slightly longer duration of surgery (210 vs 223 vs 240 minutes), higher blood loss (195 vs 275 vs 350 ml), higher rate of infections (16 vs 17 vs 47%) in group A vs B vs C. Rate of relaparotomy was low in all cohorts (0%, 6%, and 7%, resp.). Higher CA125 levels were associated with shorter OS in the entire population (median OS: group A 59 months vs group B 52 months, HR 1.26 (95%CI: 0.92-1.71) versus group C 35 months, HR 2.05 (95% CI: 1.33-3.16); log-rank p=0.002). Similarly, in the chemotherapy alone arm (median OS: group A 53 months vs group B 48 months, HR 1.24 (95% CI: 0.81-1.90) versus group C 35 months, HR 1.90 (95% CI: 1.09-3.30)) and in the surgical arm (median OS: group A 61 months vs group B 52 months, HR 1.32 (95% CI: 0.84-2.05) versus group C 35 months, HR 2.06 (95% CI: 1.00-4.26)). Median OS in group C from surgical arm favoured complete resection compared to incomplete resection (HR 0.22 (95% CI: 0.04-1.31); log-rank p=0.049). CA 125 levels at the time of relapse are associated with overall survival independent of treatment strategy. In this AGO score preselected population, the benefit from complete resection is independent from CA125.